Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LYKA LABS vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LYKA LABS AUROBINDO PHARMA LYKA LABS/
AUROBINDO PHARMA
 
P/E (TTM) x -99.4 23.0 - View Chart
P/BV x 12.5 2.4 526.4% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 LYKA LABS   AUROBINDO PHARMA
EQUITY SHARE DATA
    LYKA LABS
Mar-23
AUROBINDO PHARMA
Mar-23
LYKA LABS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs202715 28.3%   
Low Rs100397 25.1%   
Sales per share (Unadj.) Rs30.3424.2 7.1%  
Earnings per share (Unadj.) Rs-4.332.9 -13.0%  
Cash flow per share (Unadj.) Rs0.354.1 0.6%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Avg Dividend yield %00.5 0.0%  
Book value per share (Unadj.) Rs9.1458.1 2.0%  
Shares outstanding (eoy) m30.69585.94 5.2%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x5.01.3 379.9%   
Avg P/E ratio x-35.216.9 -208.5%  
P/CF ratio (eoy) x465.710.3 4,535.5%  
Price / Book Value ratio x16.51.2 1,363.5%  
Dividend payout %09.1 -0.0%   
Avg Mkt Cap Rs m4,634325,753 1.4%   
No. of employees `000NANA-   
Total wages/salary Rs m18635,223 0.5%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m931248,554 0.4%  
Other income Rs m342,906 1.2%   
Total revenues Rs m965251,460 0.4%   
Gross profit Rs m9437,070 0.3%  
Depreciation Rs m14112,446 1.1%   
Interest Rs m1191,405 8.4%   
Profit before tax Rs m-13226,125 -0.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m06,849 -0.0%   
Profit after tax Rs m-13219,277 -0.7%  
Gross profit margin %10.114.9 68.0%  
Effective tax rate %0.126.2 0.5%   
Net profit margin %-14.17.8 -182.2%  
BALANCE SHEET DATA
Current assets Rs m442214,599 0.2%   
Current liabilities Rs m326114,938 0.3%   
Net working cap to sales %12.540.1 31.1%  
Current ratio x1.41.9 72.6%  
Inventory Days Days9021 437.5%  
Debtors Days Days78966 1,203.4%  
Net fixed assets Rs m1,073176,668 0.6%   
Share capital Rs m307586 52.4%   
"Free" reserves Rs m-27267,813 -0.0%   
Net worth Rs m280268,399 0.1%   
Long term debt Rs m6386,190 10.3%   
Total assets Rs m1,515392,125 0.4%  
Interest coverage x-0.119.6 -0.6%   
Debt to equity ratio x2.30 9,877.8%  
Sales to assets ratio x0.60.6 96.9%   
Return on assets %-0.85.3 -16.0%  
Return on equity %-47.07.2 -654.0%  
Return on capital %-1.410.0 -14.1%  
Exports to sales %033.7 0.0%   
Imports to sales %015.3 0.0%   
Exports (fob) Rs mNA83,703 0.0%   
Imports (cif) Rs mNA38,060 0.0%   
Fx inflow Rs m085,483 0.0%   
Fx outflow Rs m041,447 0.0%   
Net fx Rs m044,036 0.0%   
CASH FLOW
From Operations Rs m9023,868 0.4%  
From Investments Rs m74-39,778 -0.2%  
From Financial Activity Rs m-21618,144 -1.2%  
Net Cashflow Rs m-532,298 -2.3%  

Share Holding

Indian Promoters % 54.8 48.8 112.4%  
Foreign collaborators % 0.0 3.1 -  
Indian inst/Mut Fund % 0.8 41.3 1.9%  
FIIs % 0.2 20.7 0.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 45.2 48.2 93.8%  
Shareholders   26,422 241,944 10.9%  
Pledged promoter(s) holding % 0.0 20.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LYKA LABS With:   SUN PHARMA    CIPLA    DIVIS LABORATORIES    DR. REDDYS LAB    ZYDUS LIFESCIENCES    


More on LYKA LABS vs Aurobindo Pharma

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

LYKA LABS vs Aurobindo Pharma Share Price Performance

Period LYKA LABS Aurobindo Pharma S&P BSE HEALTHCARE
1-Day -1.72% 1.82% 1.18%
1-Month -12.44% 5.96% -0.75%
1-Year 3.72% 113.07% 61.82%
3-Year CAGR 62.26% 7.78% 18.16%
5-Year CAGR 33.01% 7.18% 19.79%

* Compound Annual Growth Rate

Here are more details on the LYKA LABS share price and the Aurobindo Pharma share price.

Moving on to shareholding structures...

The promoters of LYKA LABS hold a 54.8% stake in the company. In case of Aurobindo Pharma the stake stands at 51.8%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of LYKA LABS and the shareholding pattern of Aurobindo Pharma.

Finally, a word on dividends...

In the most recent financial year, LYKA LABS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.

Aurobindo Pharma paid Rs 3.0, and its dividend payout ratio stood at 9.1%.

You may visit here to review the dividend history of LYKA LABS, and the dividend history of Aurobindo Pharma.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.